Immune carrier microsphere loaded with individualized MHC-II binding polypeptide and vaccine preparation and application thereof

By isolating T/B epitopes inside and outside individualized MHC-II-binding peptide microspheres, the problems of competitive inhibition by carrier molecules and excessive activation of T cells are solved, antibody titers are improved and side effects are reduced, adapting to human HLA diversity and achieving efficient and safe antibody production.

CN121987771APending Publication Date: 2026-05-08SHANGHAI WEIQIU BIOTECH
2 Cites 0 Cited by

Patent Information

Application Number
CN202511924977.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2025-12-19
Publication Date
2026-05-08

AI Technical Summary

Technical Problem

Existing therapeutic vaccines suffer from several problems, including immune competition between the carrier molecule and the antigen epitope, side effects caused by carrier molecule antibodies, side effects from excessive T cell activation, and difficulty in adapting to human HLA diversity, resulting in low antibody titers and high risk of side effects.

Method used

Personalized MHC-II binding peptide microspheres were used. The HLA genotype of the recipient was predicted by computer, and high-affinity MHC-II binding peptides were designed and encapsulated in the core-shell structure of the microspheres. The shell was made of thiol-containing dextran or other hydrophilic polymers to achieve internal and external isolation of T/B epitopes and avoid competitive inhibition and overactivation.

Benefits of technology

It improved antibody titers, reduced the side effects of cross-reactivity between carrier molecules and antibodies and excessive T cell activation, adapted to human HLA diversity, and achieved efficient and safe antibody production.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of immune carriers, in particular to immune carrier microspheres loaded with individualized MHC-II binding polypeptide and vaccine preparation and application of the immune carrier microspheres loaded with the individualized MHC-II binding polypeptide. The core microsphere is loaded with individualized MHC-II binding polypeptide, the sequence of the MHC-II binding polypeptide is obtained by predicting and screening based on an HLA genotyping result, and each HLA allele corresponds to at least one high-affinity MHC-II binding polypeptide; and the shell is a glucan or other polymer coating layer. The preparation method has the advantages that the T epitope and the B epitope are separately subjected to immune competitive inhibition inside and outside the microspheres, so that a better immune effect is obtained. The antibody avoids cross reaction side effects; carrier molecule diversity is reduced, and side effects caused by T cell over-activation are avoided; th1 epitopes and Th2 epitopes can be contained in the microspheres, so that antibody immunity and T cell immunity functions are generated; the particle size of the microspheres is controllable, and the immunologic function can be achieved without adjuvants.
Need to check novelty before this filing date? Find Prior Art